The focus group study was part of the ongoing CAP (Cluster randomised triAl of testing for Prostate cancer) trial, which is evaluating the population effectiveness of a single prostate specific antigen (PSA) test for prostate cancer [31]. Here, KLK3 is linked to prostate carcinoma.